


## Management of Extra-Renal Complications

### Prioritized:

1. Is widespread screening for intracranial aneurysm of all patients with ADPKD justified? If not, in which patients should screening be recommended? If screening is negative, should patients be rescreened? At which time interval?
2. When an UIA is detected, what are the indications to intervene? If an UIA is recommended for conservative management, what are the recommendations for follow-up and to reduce the risk of rupture?




KDIGO Controversies Conference on ADPKD  
Breakout Session Questions




# The vasculopathy of ADPKD



Dolichoectasia



Thoracic aortic dissection



Cervico-cephalic artery dissection

# Vascular Expression of Polycystin

MATTHEW D. GRIFFIN,\* VICENTE E. TORRES,\* JOSEPH P. GRANDE,<sup>†</sup> and  
RAJIV KUMAR\*

(J Am Soc Nephrol 8: 616–626, 1997)

# Vascular Expression of Polycystin-2

VICENTE E. TORRES,\*<sup>†</sup> YIQUIANG CAI,<sup>‡</sup> XI CHEN,\* GUANQUING Q. WU,<sup>‡</sup>  
LIN GENG,<sup>‡</sup> KATHLEEN A. CLEGHORN,<sup>†</sup> CHRISTOPHER M. JOHNSON,<sup>§</sup>  
and STEFAN SOMLO<sup>||</sup>

J Am Soc Nephrol 12: 1–9, 2001

# Polycystin 1 is required for the structural integrity of blood vessels

Keetae Kim<sup>†</sup>, Iain Drummond<sup>†</sup>, Oxana Ibraghimov-Beskrovnaya<sup>‡</sup>, Katherine Klinger<sup>†</sup>, and M. Amin Arnaout<sup>1,4</sup>

PNAS | February 15, 2000 | vol. 97 | no. 4 | 1731–1736

# Cardiac defects and renal failure in mice with targeted mutations in *Pkd2*

Guanqing Wu<sup>1,6</sup>, Glen S. Markowitz<sup>7</sup>, Li Li<sup>1</sup>, Vivette D. D'Agati<sup>7</sup>, Stephen M. Factor<sup>2</sup>, Lin Geng<sup>9</sup>,  
Sonia Tibara<sup>1</sup>, Jay Tuchman<sup>1</sup>, Yiqiang Cai<sup>1,6</sup>, Jong Hoon Park<sup>1</sup>, Janet van Adelsberg<sup>8</sup>, Harry Hou Jr<sup>3</sup>,  
Raju Kucherlapati<sup>4</sup>, Winfried Edelmann<sup>5</sup> & Stefan Somlo<sup>1,4,6</sup>

nature genetics • volume 24 • january 2000

# Pathogenic Sequence for Dissecting Aneurysm Formation in a Hypomorphic Polycystic Kidney Disease 1 Mouse Model

Sabrina Hassane, Nanna Claij, Irma S. Lantinga-van Leeuwen, J. Conny Van Munsteren,  
Natascha Van Lent, Roeland Hanemaaijer, Martijn H. Breuning, Dorien J.M. Peters and Marco  
C. DeRuiter


Arterioscler Thromb Vasc Biol. 2007;27:2177-2183

# Cardiovascular Polycystins: Insights From Autosomal Dominant Polycystic Kidney Disease and Transgenic Animal Models

Delphine Bichet, Dorien Peters, Amanda Jane Patel,  
Patrick Delmas, and Eric Honoré\*

(Trends Cardiovasc Med 2006;16:292–298)

The prevalence of unruptured intracranial aneurysms (UIAs) is 2 to 3 times higher in patients with ADPKD than in the general population



*(Pirson, JASN 2002; 13 : 269  
Neumann HP, Cerebrovas Dis Extra 2012; 2: 71  
Vlak M, Lancet Neurol 2011; 10: 626)*

## Prevalence of IA in ADPKD : Source data

**Table 22.1** Prevalence of asymptomatic saccular intracranial aneurysms in autosomal dominant polycystic kidney disease

	Chapman <i>et al.</i> (1992)	Huston <i>et al.</i> (1993)	Ruggieri <i>et al.</i> (1994)	Total
Method	Angio or CT	MRA	MRA	
Subjects ( <i>n</i> )	88	85	93	266
Mean age (yrs)	36	45	48	43
Subjects with ICA ( <i>n</i> )	4 (4.5%)	9 (10.6%)	8 (8.6%)	21 (7.9%)
ICA ( <i>n</i> )	8	9	11	28
6–10 mm	0	2	2	4
3–5	7	2	5	14
< 3	1	5	4	10

Angio, conventional angiography; CT, thin-section high-resolution contrast-enhanced computerized tomography; MRA, magnetic resonance angiography.

*(Intracranial aneurysms in autosomal dominant Polycystic kidney disease. In: Oxford Clinical Nephrology Series)*

## Prevalence of IA in ADPKD may be higher in some populations

# Screening for Intracranial Aneurysm in 355 Patients With Autosomal-Dominant Polycystic Kidney Disease

H.W. Xu, MD, PhD; Sheng Qiang Yu, MD, PhD; Chang Lin Mei, PhD; Ming Hua Li, MD, PhD

**Background and Purpose**—The association of autosomal-dominant polycystic kidney disease (ADPKD) with intracranial aneurysm (ICAN) is well known but little is known about the characteristics of ICAN in ADPKD. The purpose of this study was to investigate the prevalence and characteristics of ICAN in ADPKD.

**Methods**—We screened 355 patients with ADPKD (mean age,  $46.5 \pm 13.2$  years; range, 7 to 87 years) with 3-dimensional time-of-flight MR angiography. Size, location, and morphology of aneurysms were assessed. The prevalence and characteristics of ICAN in patients with ADPKD were evaluated. Patients with ICAN found by MR angiography and moderate renal function subsequently were recommended to undergo digital subtraction angiography for comparison.

**Results**—The prevalence of ICAN in ADPKD was 12.4% (95% CI, 8.95% to 15.82%) with an equal gender distribution. The prevalence increased as age increased, reaching a peak value of 23.3% (95% CI, 16.85 to 29.75%) in the 60- to 69-year age group. The prevalence of ICAN in patients with ADPKD with a positive family history of hemorrhagic stroke or ICAN was higher than patients with ADPKD lacking such family history (relative risk, 1.968; 95% CI, 1.57 to 2.67). The mean diameter of ICAN was  $3.85 \pm 3.25$  mm. The most frequent site of ICAN was the internal carotid artery. The result of digital subtraction angiography of 15 patients with 18 ICANs and moderate renal function corresponded to the detection of MR angiography.

**Conclusion**—The characteristics of ICAN in patients with ADPKD were different from some previous reports. Systematic screening of ICAN with 3-dimensional time-of-flight MR angiography is recommended for patients with ADPKD, particularly for adult patients ( $\geq 30$  years) or patients with a positive family history of hemorrhagic stroke or ICAN. (*Stroke*. 2011;42:204-206.)

## The characteristics of UIAs are similar in ADPKD and the general population

### ADPKD

### General population

Location in the anterior circulation

80 – 100%

80 – 90%

Multiple

18 – 30%

35%

<6 mm

80 – 90%

70 – 80%


*(Pirson, JASN 2002; 13 : 269*

*Irazabal, Clin J Am Soc Nephrol 2011; 6 : 1274*

*Vlak M, Lancet Neurol 2011; 10: 626*

*Rozenfeld AJNR, Am J Neuroradiol 2013; in press)*

In the ADPKD population, the only clinical characteristic associated with the presence of an UIA is a family history of IA



*(Pirson, JASN 2002; 13 : 269  
Irazabal, Clin J Am Soc Nephrol 2011; 6 : 1274)*



## Prevalence of IA in ADPKD according to family history : source data

**Table 22.2** Prevalence of asymptomatic ICA\* among 263 ADPKD patients according to the existence of a definite family history of ICA or subarachnoid haemorrhage

Study	Positive family history	Negative family history
Chapman <i>et al.</i> (1992)	2/29	2/59
Huston <i>et al.</i> (1993)	6/27	3/56
Ruggieri <i>et al.</i> (1994)	4/21	6/71
Total	12/77 (15.6%)	11/186 (5.9%)

P < 0.05

\*21 were saccular, 2 were fusiform.

*(Intracranial aneurysms in autosomal dominant Polycystic kidney disease. In: Oxford Clinical Nephrology Series)*

# Screening for Intracranial Aneurysm in 355 Patients With Autosomal-Dominant Polycystic Kidney Disease

H.W. Xu, MD, PhD; Sheng Qiang Yu, MD, PhD; Chang Lin Mei, PhD; Ming Hua Li, MD, PhD

**Background and Purpose**—The association of autosomal-dominant polycystic kidney disease (ADPKD) with intracranial aneurysm (ICAN) is well known but little is known about the characteristics of ICAN in ADPKD. The purpose of this study was to investigate the prevalence and characteristics of ICAN in ADPKD.

**Methods**—We screened 355 patients with ADPKD (mean age,  $46.5 \pm 13.2$  years; range, 7 to 87 years) with 3-dimensional time-of-flight MR angiography. Size, location, and morphology of aneurysms were assessed. The prevalence and characteristics of ICAN in patients with ADPKD were evaluated. Patients with ICAN found by MR angiography and moderate renal function subsequently were recommended to undergo digital subtraction angiography for comparison.

**Results**—The prevalence of ICAN in ADPKD was 12.4% (95% CI, 8.95% to 15.82%) with an equal gender distribution. The prevalence increased as age increased, reaching a peak value of 23.3% (95% CI, 16.85 to 29.75%) in the 60- to 69-year age group. The prevalence of ICAN in patients with ADPKD with a positive family history of hemorrhagic stroke or ICAN was higher than patients with ADPKD lacking such family history (relative risk, 1.968; 95% CI, 1.57 to 2.67). The mean diameter of ICAN was  $3.85 \pm 3.25$  mm. The most frequent site of ICAN was the internal carotid artery. The result of digital subtraction angiography of 15 patients with 18 ICANs and moderate renal function corresponded to the detection of MR angiography.


**Conclusion**—The characteristics of ICAN in patients with ADPKD were different from some previous reports. Systematic screening of ICAN with 3-dimensional time-of-flight MR angiography is recommended for patients with ADPKD, particularly for adult patients ( $\geq 30$  years) or patients with a positive family history of hemorrhagic stroke or ICAN. (*Stroke*. 2011;42:204-206.)

**The risk of rupture of an UIA is low,  
but rupture is devastating**

- **The vast majority of UIA remain asymptomatic both in the general population and in ADPKD patients.**
- **But rupture entails a mortality rate of 50% and treatment of a ruptured IA also carries a mortality rate of 10% and a morbidity rate of 20%**

# Should Patients with Autosomal Dominant Polycystic Kidney Disease Be Screened for Cerebral Aneurysms?

M.N. Rozenfeld, S.A. Ansari, A. Shaibani, E.J. Russell, P. Mohan, and M.C. Hurley



**Risk of rupture of UIA in the general population**

**Risk of rupture of UIA in the ADPKD population**

**Risk of prophylactic repair of an UIA**

**Decision – analysis**


**Practical attitude in ADPKD**

# Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment

## Natural history

1692 patients with UIAs  $\geq 2$  mm without (1077) or with (615) prior history of SAH




Overall annual rupture risk :  
0,7 %



# The Natural Course of Unruptured Cerebral Aneurysms in a Japanese Cohort

Natural history  
 5720 pts with UIAs  $\geq 3$  mm  
 91% incidentally

Overall annual rupture risk :  
**0,9 %**



## Other, epidemiological, risk factors for rupture of UIAs in the general population

*Studies assessing the risk of SAH in patients known to have an UIA or that had investigated the characteristics of people who experienced a SAH without previously be know to have a UIA*

### Odds ratio

- HTA 2.5
- Smoking 3.1
- Alcohol > 150 g/w 1.5

*(Clarke M. Systematic review of reviews of risk factors for Intracranial aneurysms. Neuroradiology 2008; 50: 653)*



**Risk of rupture of UIA in the general population**

**Risk of rupture of UIA in the ADPKD population**

**Risk of prophylactic repair of an UIA**

**Decision – analysis**

**Practical attitude in ADPKD**

# Natural history of IA in ADPKD patients

	Total n	Mean F-U	n rupture	n growth	n new
Belz, 2003	n = 20	15 yrs			
	-11 SAH (+)		1	1	4
	- 9 SAH (-)		0	1	1
Gibbs, 2004	n = 21	7 yrs			
	- 7 FH (+)		0	0	1
	-14 FH (-)		0	1	0
Irazabal, 2012	n = 31	6 yrs			
	-17 FH (+)		0	1	1
	-14 FH (-)		0	1	0
Jiang 2013	n = 40	> 3 yrs	0	4	?
<b>Total</b>	<b>n = 112</b>	<b>3-15 yrs</b>	<b>1</b>	<b>9</b>	<b>7/72</b>

*(Belz MM, Kidney Int 2003; 63:1824-30*

*Gibbs GF, Kidney Int 2004;65:1621-1627*

*Irazabal MV, Clin J Am Soc Nephrol 211;6:1274-85*


*Jiang T, Eur J Radiol 2013; in press)*

# Causes of Death in Autosomal Dominant Polycystic Kidney Disease<sup>1,2</sup>


Godela M. Fick, Ann M. Johnson, William S. Hammond, and Patricia A. Gabow<sup>3</sup>

(J. Am. Soc. Nephrol. 1995; 5:2048–2056)

- Medical records of 129 patients who died between 1956 and 1993 (58% had autopsy)
- A ruptured IA was the cause of death in 8 (6%)
  - Mean age at death : 37 yr
  - 7/8 before ESRD
- « Insufficiently treated hypertension in some ? ».....



**Figure 6.** Trends in causes of death in patients on renal replacement therapy for ADPKD and non-ADPKD. Adjusted for age and sex to the distribution of EU27 population in 2005. Abbreviation CV stands for cardiovascular.



*(Spithoven EM, Gansevoort RT et al. Renal replacement therapy for ADPKD in Europe : Analysis of data from the ERA-EDTA Registry Nephrol Dial Transpl, in press)*

**Risk of rupture of UIA in the general population**

**Risk of rupture of UIA in the ADPKD population**


**Risk of prophylactic repair of an UIA**

**Decision – analysis**

**Practical attitude in ADPKD**


# Poor outcome (death or serious disability) at 1 year after repair of an UIA according to age, site and size

## Surgical (n = 1917)



Overall mortality : 2.3 %  
Overall morbidity : 9.8 %

## Endovascular (n = 451)



Overall mortality : 3.1 %  
Overall morbidity : 6.4 %

**Risk of rupture of UIA in the general population**

**Risk of UIA in the ADPKD population**

**Risk of prophylactic repair of an UIA**

**Decision – analysis**

**Practical attitude in ADPKD**




# **A mathematical model of utility for single screening of asymptomatic unruptured intracranial aneurysms at the age of 50 years**


**Lucia M. Li • Diederik O. Bulters • Ramez W. Kirollos**

Acta Neurochir (2012) 154:1145–1152

a



b



## Li decision analysis : main results

- The 5-yr risk of rupture at which screening results in a gain of QALY is 13% at a screening age of 50  
8% at a screening age of 30
- This threshold risk is not decreased by increasing the prevalence to 25%
- The risk of prophylactic intervention should be reduced to <25% of that reported in ISUIA to provide a clinical benefit in the general population
- The key determinant is the individual risk of rupture

# **Familial Clustering of Ruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease**

Mark M. Belz, MD, Richard L. Hughes, MD, William D. Kaehny, MD, Ann M. Johnson, MS, Godela M. Fick-Brosnahan, MD, Michael P. Earnest, MD, and Patricia A. Gabow, MD

*American Journal of Kidney Diseases*, Vol 38, No 4 (October), 2001: pp 770-776

● Ruptured intracranial aneurysm (RICA) is a life-threatening complication of autosomal dominant polycystic kidney disease (ADPKD). A family history of RICA may be a risk factor for RICA. Six hundred eight adult members of 199 ADPKD families were interviewed, and family pedigrees were constructed. Individuals were classified as having definite, probable, or possible RICAs from evidence and history obtained in interviews. Central nervous system (CNS) events not consistent with RICA were classified as other CNS events. Seventy-seven CNS events occurred in 906 subjects with ADPKD (8.5%) versus 13 events in 823 subjects without ADPKD (1.6%;  $P < 0.0001$ ). No event in subjects without ADPKD was consistent with an RICA. Twenty-seven other (non-RICA) CNS events occurred in subjects with ADPKD (3%) versus 13 events in subjects without ADPKD (1.6%;  $P = 0.05$ ). The frequency of RICA was increased in subjects with ADPKD: 21 definite RICAs in subjects with ADPKD (2%) versus none in subjects without ADPKD ( $P < 0.001$ ); 28 definite and probable RICAs in subjects with ADPKD (3%) versus none in subjects without ADPKD ( $P < 0.001$ ); and 50 definite, probable, and possible RICAs in subjects with ADPKD (5.5%) versus none in subjects without ADPKD ( $P < 0.001$ ). The null hypothesis that RICAs are randomly distributed among subjects with ADPKD was tested for definite RICAs ( $n = 21$ ), definite and probable RICAs ( $n = 28$ ), and definite, probable, and possible RICAs ( $n = 50$ ). In the three categories, the null hypothesis was rejected at  $P$  less than 0.05,  $P$  less than 0.05, and  $P$  less than 0.005, respectively. Vascular CNS events occurred more frequently in ADPKD than non-ADPKD family members, and clustering of RICAs occurred in families with ADPKD.

© 2001 by the National Kidney Foundation, Inc.

# Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic kidney disease

T Ring<sup>1</sup> and D Spiegelhalter<sup>2</sup>

*Kidney International* (2007) **72**, 1400–1402

Patients with autosomal-dominant polycystic kidney disease (ADPKD) carry an increased risk of developing intracranial aneurysms. Bleeding from these sites is a significant complication with the events reported to cluster in some families. In this study we determined if individualized risk of aneurysm rupture can be estimated based on family history using a Bayesian random effects model. Previously reported data were used to define distributions and to construct a model that fit these data. Our results confirm that intracerebral aneurysm bleeding in ADPKD patients tends to cluster in families and that basic family history can provide a simple estimate of family-specific risk.


**Risk of rupture of UIA in the general population**

**Risk of UIA in the ADPKD population**

**Risk of prophylactic repair of an UIA**

**Decision – analysis**

**Practical attitude in ADPKD**



# Indications for prophylactic repair


Rely on 3 main factors

- IA characteristics :  
size (> 6 – 7 mm), location, morphology
- patient's age and general health
- doctor's (neuroradiologist/neurosurgeon)  
experience



## Conservative management for < 6 - 7 mm IA

- ~~Tobacco~~
- Aggressive treatment HTA
- Repeat imaging
  - At 6 months, and then annually for 3 years
  - if stable, every 2-3 yrs



**But some recommend screening in all ADPKD patients whatever the family history**

## **Screening for Intracranial Aneurysm in 355 Patients With Autosomal-Dominant Polycystic Kidney Disease**

H.W. Xu, MD, PhD; Sheng Qiang Yu, MD, PhD; Chang Lin Mei, PhD; Ming Hua Li, MD, PhD

*(Stroke. 2011;42:204-206.)*

## **Characteristics of Intracranial Aneurysms in the Else Kröner-Fresenius Registry of Autosomal Dominant Polycystic Kidney Disease**

Hartmut P.H. Neumann<sup>a</sup> Angelica Malinoc<sup>a</sup> Janina Bacher<sup>a</sup>  
Zinaida Nabulsi<sup>a</sup> Vera Ivanovas<sup>b</sup> Nadine Ortiz Bruechle<sup>g</sup>  
Irina Mader<sup>g</sup> Michael M. Hoffmann<sup>c</sup> Peter Riegler<sup>i</sup>  
Annette Kraemer-Guth<sup>f</sup> Christian Burchard<sup>h</sup> Elke Schaeffner<sup>i</sup>  
Rodolfo S. Martin<sup>k</sup> Pablo J. Azurmendi<sup>k</sup> Klaus Zerres<sup>g</sup>  
Cordula Jllg<sup>d</sup> Charis Eng<sup>l</sup> Sven Gläsker<sup>e</sup>

Cerebrovasc Dis Extra 2012;2:71–79

## **Should Patients with Autosomal Dominant Polycystic Kidney Disease Be Screened for Cerebral Aneurysms?**

M.N. Rozenfeld, S.A. Ansari, A. Shaibani, E.J. Russell, P. Mohan, and M.C. Hurley

AJNR Am J Neuroradiol ●●● 2014

Let us recognize that a family history (FH) is found in only a minority of ADPKD patients presenting with a IA rupture

## Intracranial aneurysms in autosomal dominant polycystic kidney disease.

Chauveau D, Pirson Y, Verellen-Dumoulin C, Macnicol A, Gonzalo A, Grünfeld JP.

Kidney Int. 1994 Apr;45(4):1140-6.

	FH (+)	FH (-)
<i>n pedigrees</i>	10 (18%)	45 (82%)
<i>mean n ADPKD</i>	5.2	4.1
<i>pts per families</i>		

## Characteristics of Intracranial Aneurysms in the Else Kröner-Fresenius Registry of Autosomal Dominant Polycystic Kidney Disease

Hartmut P.H. Neumann<sup>a</sup> Angelica Malinoc<sup>a</sup> Janina Bacher<sup>a</sup>  
 Zinaida Nabulsi<sup>a</sup> Vera Ivanovas<sup>b</sup> Nadine Ortiz Bruechle<sup>g</sup>  
 Irina Mader<sup>g</sup> Michael M. Hoffmann<sup>c</sup> Peter Riegler<sup>i</sup>  
 Annette Kraemer-Guth<sup>f</sup> Christian Burchard<sup>h</sup> Elke Schaeffner<sup>i</sup>  
 Rodolfo S. Martin<sup>k</sup> Pablo J. Azurmendi<sup>k</sup> Klaus Zerres<sup>g</sup>  
 Cordula Jilg<sup>d</sup> Charis Eng<sup>l</sup> Sven Gläsker<sup>e</sup>

Cerebrovasc Dis Extra 2012;2:71–79

FH (+) in only 5/27 (19%) families

**The treshhold size to intervene is  
also a matter a debate**

**Size distribution of 27 ruptures IA in patients with ADPKD**

<b>&lt; 5 mm :</b>	<b>19 %</b>
<b>5 – 9 :</b>	<b>33 %</b>
<b>10 – 24 :</b>	<b>26 %</b>
<b>&gt; 25</b>	<b>22 %</b>

**Table 2 Summary of recommendations****Recommendations for screening****Strongly consider screening**

- Patients with 2 or more family members with history of UIA or SAH
- ADPKD with family history of UIA or SAH
- Patients with coarctation of the aorta

**Possibly consider screening**

- Patients with ADPKD without family history of aneurysm
- Patients with one family member with UIA or SAH (per patient preference)

**Do not recommend screening**

- General population

**Recommendations for treatment****Strongly consider treatment with clipping or endovascular procedure**

- UIA  $\geq 12$  mm in diameter
- Symptomatic UIA
- Enlarging UIA

**Possibly consider treatment with clipping or endovascular procedure**

- 7 mm  $\leq$  UIA < 12 mm in diameter + any of the following features:
  - UIA in younger patients
  - UIA in higher-risk locations such as posterior circulation or posterior communicating artery
  - UIA with daughter sac
  - Family history of SAH
- UIA < 7 mm in diameter in younger patients + any of the following features:
  - UIA in high-risk locations such as posterior circulation or posterior communicating artery
  - UIA with daughter sac
  - Family history of SAH

**Do not recommend treatment with clipping or endovascular procedure**

- UIA < 7 mm in diameter in anterior circulation without any high-risk features such as family history of SAH or presence of daughter sac
- Asymptomatic cavernous internal carotid aneurysms

Abbreviations: ADPKD = autosomal dominant polycystic kidney disease; SAH = subarachnoid hemorrhage; UIA = unruptured intracranial aneurysm.

## Table 1. Screening considerations for intracranial aneurysms

Who should be screened for ICAs?

- (i) Any ADPKD patient with symptoms (severe or atypical headache, TIA, cranial nerve palsy)
- (ii) Patient in a high-risk occupation (pilot)
- (iii) Patient with a family history (initial screen should be prior to the time of the first event in the family)
- (iv) Patients preparing for major surgery (such as renal transplant) or who will receive long-term anticoagulation (such as for a prosthetic heart valve)
- (v) Patients with anxiety regarding an ICA
- (vi) Patients with a prior history of ICA rupture.

Screening test: MR angiogram without gadolinium.

Intervention versus observation of an ICA: based on ICA characteristics (size and location), patient characteristics (age, functional status and occupation) and operator characteristics (risk of complications).

Rescreening: Every 5 years in high-risk patients. Consider rescreening once in low-risk patients after 10 years.